Has Leslie Hilger, MD received payments from drug or device companies?

Yes. Drug and device makers reported $3,634 in general payments to Leslie Hilger, MD across 143 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Leslie Hilger, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Leslie Hilger, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Leslie Hilger, MD

Dermatopathology · Oakland, CANPI 1902901226

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.8% of the total across 143 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 16.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,164 and has fallen 61.1% since, to $453 in 2025.

$3,634in general payments, 2019–2025

Across 143 payments — averaging $25.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Genentech USA, Inc.$585
AbbVie$576
Johnson & Johnson$505
Lilly USA, LLC$304
Regeneron Healthcare Solutions, Inc.$297
Amgen$241
plus $1K from 18 others

What the payments were for

Food & beverage$3,627100%
Education$70%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Genentech USA, Inc.	25	$585
AbbVie	28	$576
Johnson & Johnson	18	$505
Lilly USA, LLC	9	$304
Regeneron Healthcare Solutions, Inc.	8	$297
Amgen	10	$241
Sanofi	5	$174
Novartis	5	$151
Janssen Scientific Affairs, LLC	1	$125
Pfizer	7	$118
LEO Pharma Inc.	3	$71
Sun Pharmaceutical Industries Inc.	3	$61
Boehringer Ingelheim	2	$59
Dermira, Inc.	2	$58
Galderma Laboratories, L.p.	3	$52
E.r. Squibb & Sons, L.L.C.	2	$49
UCB, Inc.	2	$37
Strata Skin Sciences, Inc.	3	$36
Organon	1	$30
Biofrontera Inc.	1	$27
Mayne Pharma Commercial LLC	1	$25
Stemline Therapeutics Inc.	1	$18
Incyte Corporation	1	$18
Pierre Fabre Pharmaceuticals, Inc.	2	$18

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,634 in reported general payments places this provider in the 80th percentile of 76 dermatopathology providers in California.

See all dermatopathology providers in California →

Medicare billing

Part B allowed, 2024

$407,992

Medicare patients

1,073

Services billed

4,728

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Clobetasol Propionate	83	$6,085
Metronidazole	46	$3,246
Isotretinoin	13	$3,014
Mometasone Furoate	129	$2,777
Econazole Nitrate	60	$1,806
Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc	26	$1,195
Fluocinonide	21	$1,169
Acyclovir	48	$962
Fluorouracil	17	$946
Doxycycline Hyclate	14	$921
Ketoconazole	32	$756
Imiquimod	15	$744
Doxepin Hcl	14	$653
Hydroxyzine Hcl	24	$577
Mupirocin	32	$300

Paid to pharmacies, not to this prescriber.

Other dermatopathology in Oakland

Kwame DeniankeOakland$232
Christiane QuerfeldDuarte$107K
Brittney de ClerckLos Angeles$56K
Brook Brouhala Jolla$20K
Vishwas ParekhDuarte$13K
Susan Detwilerla Jolla$7K
Mandy Ramanila Canada$7K
Curt VogelEncinitas$7K
Karen Sherwoodla Canada$6K
John Honchla Canada$6K

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →